Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
The bottom line is that Claxton and Culyer believe, and are on record as saying, that a therapy or procedure is not cost effective if “the health benefits that it is estimated could be gained from the technology are less than those estimated to be forgone by other patients as other procedures are necessarily curtailed or not undertaken. It is this comparison of health gained and health forgone that is at the heart of the rationale of cost-effectiveness analysis”. To estimate whether the gains made …
Competing interest: None.
This debate is now closed.
Read the full text or download the PDF:
Other content recommended for you
- Ageism and equality
- Rights, responsibilities and NICE: a rejoinder to Harris
- Value based pricing for NHS drugs: an opportunity not to be missed?
- NICE is not cost effective
- Not a NICE fallacy: a reply to Dr Quigley
- Wickedness or folly? The ethics of NICE’s decisions
- Research ethics and evidence based medicine
- Helping poorer countries make locally informed health decisions
- NICE: faster access to modern treatments? Analysis of guidance on health technologies
- Incremental benefits of novel pharmaceuticals in the UK: a cross-sectional analysis of NICE technology appraisals from 2010 to 2020